Pliant Therapeutics Inc. /zigman2/quotes/218669590/composite PLRX -6.25% upsized its planned initial public offering on Tuesday, saying in a regulatory filing that it plans to offer 9 million shares, up from an earlier 6 million. The shares are expected to price at $14 to $16, raising $144 million at the top of the range. Citigroup, Cowen, Piper Sandler and Needham and Company are underwriting the deal. "We are a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis," the company says in its IPO documents. Proceeds of the deal will be used to fund clinical development of lead product candidate PLN-74809, and to fund R&D for early-stage oncology and muscular dystrophy programs. The remainder will be used for general corporate purposes.